[1] |
Pathak K, Hart S, Lande L. Nontuberculous Mycobacteria Lung Disease (NTM-LD): Current Recommendations on Diagnosis, Treatment, and Patient Management. Int J Gen Med, 2022, 15:7619-7629. doi:10.2147/IJGM.S272690.
doi: 10.2147/IJGM.S272690
pmid: 36213301
|
[2] |
聂琦, 周勇, 陈华, 等. 非结核分枝杆菌病流行病学研究进展.中华临床感染病杂志, 2020, 13(5):394-400. doi:10.3760/cma.j.issn.1674-2397.2020.05.014.
doi: 10.3760/cma.j.issn.1674-2397.2020.05.014
|
[3] |
Yan M, Brode SK, Marras TK. The Other Nontuberculous Mycobacteria: Clinical Aspects of Lung Disease Caused by Less Common Slowly Growing Nontuberculous Mycobacteria Species. Chest, 2023, 163(2):281-291. doi:10.1016/j.chest.2022.09.025.
doi: 10.1016/j.chest.2022.09.025
URL
|
[4] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11):918-946. doi:10.3760/cma.j.cn112147-20200508-00570.
doi: 10.3760/cma.j.cn112147-20200508-00570
|
[5] |
中华医学会结核病学分会, 分枝杆菌菌种中文译名原则专家共识编写组. 分枝杆菌菌种中文译名原则专家共识. 中华结核和呼吸杂志, 2018, 41(7):522-528. doi:10.3760/cma.j.issn.1001-0939.2018.07.003.
doi: 10.3760/cma.j.issn.1001-0939.2018.07.003
|
[6] |
Yagi K, Morimoto K, Ishii M, et al. Clinical characteristics of pulmonary Mycobacterium lentiflavum disease in adult patients. Int J Infect Dis, 2018, 67:65-69. doi:10.1016/j.ijid.2017.12.001.
doi: 10.1016/j.ijid.2017.12.001
URL
|
[7] |
Springer B, Wu WK, Bodmer T, et al. Isolation and characteri-zation of a unique group of slowly growing Mycobacteria:description of Mycobacterium lentiflavum sp.nov. J Clin Microbiol, 1996, 34(5):1100-1107.doi:10.1128/jcm.34.5.1100-1107.1996.
doi: 10.1128/jcm.34.5.1100-1107.1996
pmid: 8727884
|
[8] |
van Ingen J, Totten SE, Heifets LB, et al. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents, 2012, 39(2):173-176. doi:10.1016/j.ijantimicag.2011.09.019.
doi: 10.1016/j.ijantimicag.2011.09.019
URL
|
[9] |
Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J, 2013, 42(6):1604-1613. doi:10.1183/09031936.00149212.
doi: 10.1183/09031936.00149212
pmid: 23598956
|
[10] |
López-Roa P, Aznar E, Cacho J, et al. Epidemiology of Non-Tuberculous Mycobacteria isolated from clinical specimens in Madrid, Spain, from 2013 to 2017. Eur J Clin Microbiol Infect Dis, 2020, 39(6):1089-1094. doi:10.1007/s10096-020-03826-7.
doi: 10.1007/s10096-020-03826-7
|
[11] |
Pan X, Zhou Y, Li Z, et al. Investigation of non-tuberculous mycobacteria in a primary hospital from southeastern China. J Infect Dev Ctries, 2019, 13(12):1095-1100. doi:10.3855/jidc.11772.
doi: 10.3855/jidc.11772
URL
|
[12] |
杨宝友, 李仲兴. 慢生黄分枝杆菌及其感染的研究进展. 河北医科大学学报, 2009, 30(11):1220-1223. doi:10.3969/j.issn.1007-3205.2009.11.046.
doi: 10.3969/j.issn.1007-3205.2009.11.046
|
[13] |
Shin S, Yoon JH, Song SH, et al. Isolation of Mycobacterium lentiflavum from a patient with a lung destroyed by tuberculosis. Korean J Lab Med, 2007, 27(2):124-127. doi:10.3343/kjlm.2007.27.2.124.
doi: 10.3343/kjlm.2007.27.2.124
pmid: 18094563
|
[14] |
Brown Elliott BA, Wallace RJ Jr. Comparison of In Vitro Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials against Isolates of Nontuberculous Mycobacteria. Antimicrob Agents Chemother, 2021, 65(7):e0007921. doi:10.1128/AAC.00079-21.
doi: 10.1128/AAC.00079-21
URL
|
[15] |
Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res, 2020, 152(3):185-226. doi:10.4103/ijmr.IJMR_902_20.
doi: 10.4103/ijmr.IJMR_902_20
URL
|
[16] |
Safdar A, Han XY. Mycobacterium lentiflavum, a recently identified slow-growing mycobacterial species: clinical significance in immunosuppressed cancer patients and summary of reported cases of infection. Eur J Clin Microbiol Infect Dis, 2005, 24(8):554-558. doi:10.1007/s10096-005-1375-x.
doi: 10.1007/s10096-005-1375-x
URL
|